SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                 FORM 10-QSB/A2

                                    MARK ONE

|X|   Quarterly Report Pursuant to Section 13 or 15(d) of the Securities
      Exchange Act of 1934 for the Quarterly Period ended April 30, 2005

|_|   Transition Report Pursuant to Section 13 or 15(d) of the Securities
      Exchange Act of 1934 for the transition period from _________
      to____________

COMMISSION FILE NUMBER: 0-50062

                          CELL POWER TECHNOLOGIES, INC.
        (Exact name of small business issuer as specified in its charter)


             Florida                                   59-1082273
  (State or other jurisdiction of         (I.R.S. Employer Identification No.)
   incorporation or organization)


              1428 36TH STREET, SUITE 205, BROOKLYN, NEW YORK 11218
          (Address of principal executive offices, including zip code)

                                 (718) 436-7931
                (Issuer's telephone number, including area code)

Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes |X| No |_|

As of August 11, 2005, the small business issuer had outstanding 32,157,560
shares of common stock.

Transitional Small Business disclosure format (check one) Yes |_| No |X|




                                   INDEX PAGE

                         PART I -- FINANCIAL INFORMATION

                                                                           Page
                                                                          Number

Forward Looking Statements                                                   (i)

Item 1 - Financial Statements (unaudited)

  Condensed Consolidated Balance Sheet at April 30, 2005                     1-2

Condensed Consolidated Statements of Operations for the six and
three months ended April 30, 2005 and 2004 and for the period from
September 23, 2003 (inception) to April 30, 2005                               3

Condensed Consolidated Statement of Changes in Stockholders'
(Deficiency) Equity for the six and three months ended April 30, 2005
and for the period from September 23, 2003 (inception) to April 30, 2005       4

Condensed Consolidated Statements of Cash Flows for the six and
three months ended April 30, 2005 and 2004 and for the period from
September 23, 2003 (inception) to April 30, 2005                             5-6

Notes to the Condensed Consolidated Financial Statements                       7

Item 2 - Plan of Operation                                                    11

Item 3 - Controls and Procedures                                              15

                           PART II--OTHER INFORMATION

Item 1 - Legal Proceedings                                                    17

Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds          17

Item 3 - Defaults upon Senior Securities                                      17

Item 4 - Submission of Matters to a Vote of Security Holders                  17

Item 5 - Other Information                                                    17

Item 6 - Exhibits and Reports on Form 8-K                                     17

Signatures                                                                    18



                           FORWARD LOOKING STATEMENTS

The following discussion and explanations should be read in conjunction with the
financial statements and related notes contained elsewhere in this Form 10-QSB.
Certain statements made in this discussion are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by terminology such as "may",
"will", "should", "expects", "intends", "anticipates", "believes", "estimates",
"predicts", or "continue" or the negative of these terms or other comparable
terminology. Because forward-looking statements involve risks and uncertainties,
there are important factors that could cause actual results to differ materially
from those expressed or implied by these forward-looking statements. Although
Cell Power believes that expectations reflected in the forward-looking
statements are reasonable, it cannot guarantee future results, performance or
achievements. Moreover, neither Cell Power nor any other person assumes
responsibility for the accuracy and completeness of these forward-looking
statements. Cell Power is under no duty to update any forward-looking statements
after the date of this report to conform such statements to actual results.

                                       (i)




                  CELL POWER TECHNOLOGIES, INC. AND SUBSIDIARY
                          (A Development Stage Company)
                      CONDENSED CONSOLIDATED BALANCE SHEET
                                   (UNAUDITED)

                                 April 30, 2005

                                     ASSETS

CURRENT ASSETS

Cash                                                                    $ 18,284
Accounts receivable                                                      188,145
Prepaid expense                                                           17,500
                                                                        --------

TOTAL CURRENT ASSETS                                                     223,929


INTANGIBLE ASSETS, net of accumulated amortization of $47,500            232,510
                                                                        --------

TOTAL ASSETS                                                            $456,439
                                                                        ========


            See Notes to Condensed Consolidated Financial Statements.

                                        1




                  CELL POWER TECHNOLOGIES, INC. AND SUBSIDIARY
                          (A Development Stage Company)
                      CONDENSED CONSOLIDATED BALANCE SHEET
                                   (UNAUDITED)

                                 April 30, 2005

                      LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES

Accounts payable                                                    $    41,232
                                                                    -----------

TOTAL CURRENT LIABILITIES                                                41,232
                                                                    -----------

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS' EQUITY
Common stock, no par value, 100,000,000 shares authorized;
32,157,560 shares issued and outstanding                              2,531,644
Paid-in capital deficiency                                             (412,801)
Deficit accumulated during the development stage                     (1,645,303)
Deferred compensation                                                   (58,333)
                                                                    -----------

TOTAL STOCKHOLDERS' EQUITY                                              415,207
                                                                    -----------

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY                          $   456,439
                                                                    ===========


            See Notes to Condensed Consolidated Financial Statements.

                                        2




                  CELL POWER TECHNOLOGIES, INC. AND SUBSIDIARY
                          (A Development Stage Company)
                 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (UNAUDITED)



                                                                                For the
                                                                              Period from
                                                                             September 22,
                                              For the Six    For the Six          2003        For the Three   For the Three
                                              Months Ended   Months Ended    (Inception) to   Months Ended    Months Ended
                                                April 30,      April 30,        April 30,       April 30,       April 30,
                                                  2005           2004             2005            2005            2004
                                              ------------    ------------    ------------    ------------    ------------
                                                                                               
REVENUE
Product sales                                 $    164,445    $         --    $    195,695    $    164,445    $         --
Royalties                                           29,910          56,426         124,954           6,210          14,017
                                              ------------    ------------    ------------    ------------    ------------
TOTAL REVENUE                                      194,355          56,426         320,649         170,655          14,017
                                              ------------    ------------    ------------    ------------    ------------

COST OF GOODS SOLD
Product costs                                      151,420              --         167,999         150,020              --
Amortization of intangibles                         15,000          15,000          47,500           7,500           7,500
                                              ------------    ------------    ------------    ------------    ------------
TOTAL COST OF GOODS SOLD                           166,420          15,000         215,499         157,520           7,500
                                              ------------    ------------    ------------    ------------    ------------
GROSS PROFIT                                        27,935          41,426         105,150          13,135           6,517
                                              ------------    ------------    ------------    ------------    ------------

OPERATING EXPENSES
Consulting fees                                    178,500         265,000         789,250          77,000         125,000
Stock based compensation to consultants            145,467          85,999         399,266          35,000          85,999
Professional fees                                  154,142          30,000         314,508          77,378          30,000
Officer's salary                                    20,000          67,251         139,160              --          33,570
Marketing and other                                 45,370           8,058         121,172          16,340           7,325
                                              ------------    ------------    ------------    ------------    ------------

TOTAL OPERATING EXPENSES                           543,479         456,308       1,763,356         205,718         281,894
                                              ------------    ------------    ------------    ------------    ------------

OPERATING LOSS                                    (515,544)       (414,882)     (1,658,206)       (192,583)       (275,377)
                                              ------------    ------------    ------------    ------------    ------------

OTHER (INCOME) EXPENSES
Interest expense - related parties                      --          35,973          62,974              --          10,910
Interest expense                                        --           5,235          21,000              --           2,617
Interest income                                     (1,107)             --          (1,107)           (417)             --
                                              ------------    ------------    ------------    ------------    ------------

TOTAL OTHER (INCOME) EXPENSES                       (1,107)         41,208          82,867            (417)         13,527
                                              ------------    ------------    ------------    ------------    ------------

NET LOSS                                      $   (514,437)   $   (456,090)   $ (1,741,073)   $   (192,166)   $   (288,904)
                                              ============    ============    ============    ============    ============

Basic and diluted net loss per common share   $      (0.02)   $      (0.02)                   $      (0.01)   $      (0.01)
                                              ============    ============                    ============    ============

Weighed-average common shares outstanding       32,157,560      27,050,549                      32,157,560      28,477,778
                                              ============    ============                    ============    ============



            See Notes to Condensed Consolidated Financial Statements.

                                        3




                  CELL POWER TECHNOLOGIES, INC. AND SUBSIDIARY
                          (A Development Stage Company)
                   CONDENSED CONSOLIDATED STATEMENT OF CHANGES
                      IN STOCKHOLDERS' (DEFICIENCY) EQUITY

          Period from September 22, 2003 (Inception) to April 30, 2005





                                                                                    Deficit
                                                                                   Accumulated
                                                Common Stock           Paid-in     During the    Stock
                                           -----------------------     Capital     Development Subscription  Deferred
                                             Shares       Amount      Deficiency      Stage     Receivable Compensation    Total
                                           ----------   -----------   ---------    -----------    -----    ---------    -----------

                                                                                                   
BALANCE - September 22, 2003 (Inception)           --   $        --   $      --    $        --    $  --    $      --    $        --

Issuance of common stock at inception
 for $.00001  per share                    22,600,000           226          --             --     (226)          --             --
Issuance of common stock in connection
 with purchase of intangible assets at
 October 3, 2003 for $.00001 per share      1,000,000            10          --             --       --           --             10
Collection of stock subscription
 receivable on October 24, 2003                    --            --          --             --      100           --            100
Net loss                                           --            --          --        (95,770)      --           --        (95,770)
                                           ----------   -----------   ---------    -----------    -----    ---------    -----------
BALANCE - October 31, 2003                 23,600,000           236          --        (95,770)    (126)          --        (95,660)

Effects of reverse merger at
 November 3, 2003:
Capitalization of LLC's accumulated
 deficit at time of recapitalization               --            --     (95,770)        95,770       --           --             --
Equity of e-The Movie Networks,
 Inc. at time of recapitalization           2,100,000        28,030    (328,030)            --       --           --       (300,000)
Stock options issued to consultant
 for services on January 22, 2004                  --            --      10,999             --       --           --         10,999
Issuance of common stock to consultants
 for services on February 12, 2004          3,000,000       300,000          --             --       --     (300,000)            --
Issuance of common stock for $.20
 per share on March 10, 2004                  250,000        50,000          --             --       --           --         50,000
Collection of stock subscription
 receivable on March 15, 2004                      --            --          --             --      126           --            126
Issuance of common stock for $.75
 per share and warrants on June 11,
 2004, net of issuance costs of $26,600       864,000       621,400          --             --       --           --        621,400
Issuance of common stock for $.75
 per share and warrants on July 30,
 2004, net of issuance costs of $98,292     1,090,560       719,602          --             --       --           --        719,602
Issuance of common stock for
 $.75 per share and warrants on
 September 1, 2004, net of
 issuance costs of $51,600                    672,000       452,400          --             --       --           --        452,400
Issuance of common stock to consultants
 for services on September 24, 2004           250,000       140,000          --             --       --     (140,000)            --
Issuance of common stock for $.75 per share
 and warrants on October 6, 2004, net of
 issuance costs of $26,624                    320,000       213,376          --             --       --           --        213,376
Issuance of common stock to consultants
 for services on October 20, 2004              11,000         6,600          --             --       --           --          6,600
Amortization of deferred consulting fees           --            --          --             --       --      236,200        236,200
Net loss                                           --            --          --     (1,130,866)      --           --     (1,130,866)
BALANCE - October 31, 2004                 32,157,560     2,531,644    (412,801)    (1,130,866)      --     (203,800)       784,177
                                           ----------   -----------   ---------    -----------    -----    ---------    -----------
 Amortization of deferred consulting fees          --            --          --             --       --      145,467        145,467
 Net loss                                          --            --          --       (514,437)      --           --       (514,437)
                                           ----------   -----------   ---------    -----------    -----    ---------    -----------
BALANCE - April 30, 2005 (UNAUDITED)       32,157,560   $ 2,531,644   $(412,801)   $(1,645,303)   $  --    $ (58,333)   $   415,207
                                           ==========   ===========   =========    ===========    =====    ==========   ===========



            See Notes to Condensed Consolidated Financial Statements.

                                        4



                  CELL POWER TECHNOLOGIES, INC. AND SUBSIDIARY
                          (A Development Stage Company)
                 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (UNAUDITED)




                                                                                                          For the
                                                                                                        Period from
                                                                                                       September 22,
                                                                         For the Six     For the Six       2003
                                                                         Months Ended    Months Ended  (Inception) to
                                                                          April 30,       April 30,      April 30,
                                                                            2005            2004           2005
                                                                         -----------    -----------    -----------
                                                                                              
CASH FLOWS FROM OPERATING ACTIVITIES
  Net loss                                                               $  (514,437)   $  (456,090)   $(1,741,073)
                                                                         -----------    -----------    -----------
Adjustments to reconcile net loss to net cash used
  in operating activities:
Amortization of deferred consulting fees                                     145,467         75,000        381,667
Stock issued for services                                                         --             --          6,600
Stock options issued for services                                                 --         10,999         10,999
Amortization of intangibles                                                   15,000         15,000         47,500
Changes in operating assets and liabilities:
Increase in accounts receivable                                             (188,145)            --       (188,145)
Decrease in prepaid expenses - related party                                      --         35,000             --
Increase in prepaid expenses                                                 (17,500)            --        (17,500)
Increase in accounts payable                                                  24,424        140,000         41,232
Increase in accrued payroll                                                       --         44,668             --
Increase in accrued interest - related parties                                    --         35,973             --
Increase in accrued interest                                                      --          5,235             --
Decrease in deferred revenue                                                      --        (30,000)       (30,000)
                                                                         -----------    -----------    -----------

 NET CASH USED IN OPERATING
ACTIVITIES                                                                  (535,191)      (124,215)    (1,488,720)
                                                                         -----------    -----------    -----------

CASH FLOWS USED IN INVESTING ACTIVITIES
Purchase of intangible assets                                                     --             --       (100,000)
                                                                         -----------    -----------    -----------

CASH FLOWS FROM FINANCING ACTIVITIES
Repurchase of stock purchase liability                                            --             --       (300,000)
Advances from related parties                                                     --             --        300,000
Repayment of advances from related parties                                        --             --       (300,000)
Proceeds from notes payable - related parties                                     --             --        600,000
Repayment of notes payable -related parties                                       --             --       (600,000)
Repayment of notes payable assumed                                                --             --       (150,000)
Proceeds from issuance of common stock (net of
    stock issue costs of $203,116)                                                --         50,000      2,056,778
Collection of stock subscription receivable                                       --            126            226
                                                                         -----------    -----------    -----------

NET CASH PROVIDED BY FINANCING
ACTIVITIES                                                               $        --    $    50,126    $ 1,607,004
                                                                         -----------    -----------    -----------



            See Notes to Condensed Consolidated Financial Statements

                                        5




                  CELL POWER TECHNOLOGIES, INC. AND SUBSIDIARY
                          (A Development Stage Company)
                CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS,
                                   (UNAUDITED)



                                                                     For the
                                                                   Period from
                                                                  September 22,
                                    For the Six    For the Six        2003
                                    Months Ended   Months Ended   (Inception) to
                                     April 30,      April 30,       April 30,
                                       2005           2004            2005
                                     ---------      ---------      ---------

NET (DECREASE) INCREASE IN CASH      $(535,191)     $ (74,089)     $  18,284

CASH - Beginning of period             553,475         93,994             --
                                     ---------      ---------      ---------

CASH - End of period                 $  18,284      $  19,905      $  18,284
                                     =========      =========      =========


SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION

Cash paid during the periods for:

Interest                             $      --      $      --      $  83,975
Taxes                                    1,700                         1,700

            See Notes to Condensed Consolidated Financial Statements.

                                        6




                          CELL POWER TECHNOLOGIES, INC.
                          (A Development Stage Company)

              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - THE COMPANY

ORGANIZATION

Pursuant to the terms and conditions of an exchange agreement effective November
3, 2003 (the "Exchange Agreement"), e-The Movie Network, Inc. ("ETMV"), now
known as Cell Power Technologies, Inc. ("Cell Power" or the "Company"), a
Florida Corporation, acquired all the outstanding membership interests of Cell
Power Technologies LLC ("Cell Power LLC"), a Delaware limited liability company
engaged in the marketing and distribution of portable cell phone batteries.

Immediately prior to the consummation of the Exchange Agreement, ETMV was an
inactive public shell. Pursuant to the Exchange Agreement, ETMV repurchased
20,000,000 shares of its common stock for $300,000, which it accounted for as a
treasury stock transaction. ETMV subsequently cancelled the shares and then
issued 23,600,000 of its unregistered shares of common stock for 100% of the
outstanding membership units of Cell Power LLC. Each membership unit of Cell
Power LLC was exchanged for 100,000 shares of ETMV common stock. As a result of
this exchange, the members of Cell Power LLC gained voting control of ETMV and,
thus, the exchange was accounted for as a reverse acquisition and Cell Power LLC
became a wholly-owned subsidiary of ETMV.

The accompanying financial statements set forth in this report for periods prior
to the recapitalization, are the financial statements of Cell Power LLC, which
have been retroactively restated to give effect to the exchange for Cell Power's
common stock, no par value (the "Common Stock"). Cell Power and its subsidiary,
Cell Power LLC, are collectively referred to as the "Company".

On April 29, 2004, ETMV changed its name to Cell Power Technologies, Inc.

DESCRIPTION OF BUSINESS AND DEVELOPMENT STAGE OPERATIONS

The Company acquired certain revenue/royalty rights, product purchasing rights
and exclusive sub-distribution rights, in certain markets in the western
hemisphere, for "Cellboost" for a period of ten years. Cellboost is a compact,
non-rechargeable, and disposable cellular telephone battery. A substantial
amount of the Company's time and capital resources are being devoted to
developing its plan to distribute Cellboost.

In addition to developing markets under the rights described above, the
Company's other development stage activities include raising capital of which
the Company has raised approximately $2 million to date through sales of its
common stock. As a development stage company, the Company is subject to all of
the risks and uncertainties that are associated with starting a new business
(See Note 2).

NOTE 2 - GOING CONCERN AND MANAGEMENT'S PLAN

The Company's condensed consolidated financial statements have been prepared
assuming the Company will continue as a going concern. The Company has incurred
accumulated net losses of $1,741,073 since its inception, has working capital of
$182,697 and stockholders' equity of $415,207 and has entered into consulting
and other contractual commitments. The Company has significantly limited capital
resources and will require additional funding in order to sustain its
operations, market its products and execute its overall business plan. The
Company expects to incur additional losses in the foreseeable future. There is
no assurance that the Company will generate revenue or raise the funds that it
needs to maintain its operation. These conditions raise substantial doubt about
the Company's ability to continue as a going concern.

                                        7




The Company's ability to continue to operate as a going concern is substantially
dependent on its ability to generate operating cash flow through the execution
of its business plan and secure funding sufficient to provide for the working
capital needs of the business. The financial statements do not include any
adjustments that might result from the outcome of this uncertainty. Management
is currently in the process of executing its business plan. There can be no
assurance that management will be successful in implementing its business plan
or that the successful implementation of such business plan will actually
improve the Company's operating results.

NOTE 3 - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION

The accompanying condensed consolidated financial statements contained herein
have been prepared in accordance with accounting principles generally accepted
in the United States of America for interim financial statements, the
instructions to Form 10-QSB and Item 310 of Regulation S-B. Accordingly, these
financial statements do not include all the information and footnotes required
by accounting principles generally accepted in the United States of America for
annual financial statements. In the opinion of management, the accompanying
condensed consolidated financial statements contain all the adjustments
necessary (consisting only of normal recurring accruals) to make the financial
position of the Company at April 30, 2005, and its results of operations and
cash flows for the six months ended April, 2005 not misleading. Operating
results for the six months ended April 30, 2005 are not necessarily indicative
of the results that may be expected for the fiscal year ending October 31, 2005.

PRINCIPLES OF CONSOLIDATION

The accompanying condensed consolidated financial statements include the
accounts of Cell Power and its wholly owned subsidiary Cell Power LLC. All
significant intercompany balances and transactions have been eliminated.

REVENUE RECOGNITION

The Company generates revenue from two specific sources; (a) royalties on the
sale of individual Cellboost units generated by other entities in certain
markets; and (b) Cellboost product sales generated by the Company. Revenues
generated from either royalty rights or Company product sales are recognized
when persuasive evidence of an arrangement exists pursuant to which units are
shipped, the fee is fixed and determinable and collectibility is probable.
Revenues from royalties of Cellboost units were $29,910 and $56,426 for the six
months ended April 30, 2005 and 2004, respectively and $6,210 and $14,017 for
the three months ended April 30, 2005 and 2004, respectively. Revenues from the
distribution of the Cellboost product during the six and three months ended
April 30, 2005 was $164,445. The Company did not generate revenues from the
distribution of the product for the 2004 periods.

EMPLOYEE STOCK OPTIONS

As permitted under SFAS No. 148, "Accounting for Stock-Based
Compensation-Transition and Disclosure," which amended SFAS No. 123 ("SFAS
123"), "Accounting for Stock Based Compensation," the Company has elected to

                                        8




continue to follow the intrinsic value method in accounting for its stock-based
employee compensation arrangements, as defined by Accounting Principles Board
Opinion("APB") No. 25, Accounting for Stock Issued to Employees," and related
interpretations including Financial Accounting Standards Board Interpretations
No. 44, "Accounting for Certain Transactions Involving Stock Compensation," an
interpretation of APB No. 25.

The following table illustrates the effect on net loss and net loss per share as
if the Company had applied the fair value recognition provisions of SFAS 123 to
stock-based employee compensation for the six and three months ended April 30,
2005 and 2004, respectively:





                                            Six Months Ended      Three Months Ended
                                               April 30,                April 30,
                                          2005         2004         2005         2004
                                        ---------    ---------    ---------    ---------

                                                                   
Net loss as reported                    $(514,437)   $(456,090)   $(192,166)   $(288,904)

Deduct: Total stock-based employee
     compensation expense determined
     under fair value based method
     for all awards, net of related
     tax effects                           (4,514)      (4,514)      (2,257)      (2,168)
                                        ---------    ---------    ---------    ---------

     Pro forma net loss                 $(518,951)   $(460,604)   $(194,423)   $(291,072)
                                        =========    =========    =========    =========

Net loss per share, basic and diluted
     as reported                        $   (0.02)   $   (0.02)   $   (0.01)   $   (0.01)
                                        =========    =========    =========    =========

     Pro forma net loss per share,
      basic and diluted                 $   (0.02)   $   (0.02)   $   (0.01)   $   (0.01)
                                        =========    =========    =========    =========


NOTE 4 - NET LOSS PER SHARE

Basic net loss per share is computed by dividing net loss applicable to common
shares by the number of weighted-average common shares outstanding during the
period. Common stock equivalents have been excluded from the weighted-average
shares for the six and three months ended April 30, 2005 and 2004, respectively,
as their inclusion would be antidilutive. Potentially dilutive securities
include an aggregate of 4,190,016 and 1,014,000, stock options and warrants for
the purchase of common stock at April 30, 2005 and 2004, respectively.

NOTE 5 - SIGNIFICANT CUSTOMERS AND SUPPLIERS

The Company's revenue was generated entirely from royalties received from E & S
International Enterprises, Inc. ("E & S"), and the sale of Cellboost units to
two customers.

NOTE 6 - COMMITMENTS AND CONTINGENCIES

CONSULTING SERVICES CONTRACTS

In October 2003, the Company entered into a management services agreement with
an entity that was considered to be a related party prior to the Exchange
Agreement. The original terms of the agreement provided that the Company receive
general business and management services for monthly payments of $35,000 for
five years. In December 2004, the Company and the consultant amended the
agreement to reduce the required monthly payments to $17,500 commencing January
2005. The Company incurred $140,000 and $52,500 of fees under this contract
during the six and three months ended April 30, 2005, respectively and $210,000
and $105,000 for the six and three months ended April 30, 2004, respectively.

                                        9




In January 2004, the Company entered into a separate consulting services
agreement for corporate finance advisory and business development services. The
contract provides for monthly payments of $5,000 for six months and an option to
purchase common stock of the Company. The option, which expires January 2014,
provides for the purchase of 514,000 shares of the Company's common stock at an
exercise price of $0.75 per share and has a fair value of $10,999. In December
2004, the Company and the consultant entered into an amendment to the consulting
agreement pursuant to which beginning January 1, 2005 and continuing on a
month-to-month basis, the consultant will receive monthly payments of $3,000.
The Company paid $13,000 of fees under this contract during the six months ended
April 30, 2005. The agreement was terminated as of February 2005 upon the mutual
agreement of the Company and the Consultant.

EMPLOYMENT AGREEMENT

The Company entered into a three-year employment agreement, effective November
1, 2003, with its Chief Executive Officer and President. The agreement provides
for a salary of $120,000 per annum, incentive bonuses and options to purchase
500,000 shares of the Company's common stock, pursuant to terms in the
Agreement. In December 2004, the Company and its Chief Executive Officer entered
into an amendment to the employment agreement pursuant to which beginning
January 1, 2005 and continuing through the term of the Agreement, the Chief
Executive Officer is not entitled to a salary. Compensation expense under this
agreement amounted to $20,000 and $0 for the six and three months ended April
30, 2005, respectively and $67,251 and $33,570 for the six and three months
ended April 30, 2004, respectively and is presented as officer's salary in the
accompanying condensed consolidated statement of operations.

AGREEMENT WITH GLOBAL LINK TECHNOLOGIES, INC.

In January 2005, the Company received a letter from or on behalf of Global Link
Technologies, Inc. ("GBLK") together with a document titled First Amendment to
the Amended and Restated Asset Purchase Agreement (the "First Amendment"). The
First Amendment, which the Company believes was inappropriately obtained by GBLK
and, as a result, is not valid, provides that the royalty fees payable to GBLK
are payable in perpetuity. The Company does not believe that the First Amendment
is enforceable and intends to vigorously defend against any claim GBLK may
initiate regarding the payment of royalties after 2005. GBLK has also
communicated to the Company that it may have retained certain rights under the
Amended Agreement with respect to Latin and South America and that through
certain of Company's actions or inactions the Company may be in breach of such
agreement. The Company believes that GBLK's contentions are without merit. GBLK
has not initiated any formal claims to date with respect to these assertions
however; the Company cannot guarantee that it would be successful in its defense
against any claims GBLK may initiate with respect to these contentions.

                                       10




ITEM 2. PLAN OF OPERATION

The following analysis of the financial condition of the Company should be read
in conjunction with the condensed consolidated financial statements included
elsewhere herein. All statements in this Form 10-QSB related to Cell Power
Technologies, Inc. and Subsidiaries ongoing financial operations and expected
future results constitute forward-looking statements. The actual results may
differ materially from those anticipated or expressed in such statements.

OVERVIEW AND HISTORY

Pursuant to an exclusive license agreement entered into between the patent
holder of the "Cellboost" battery and an exclusive distributor and a sub-license
agreement entered into between such exclusive distributor and a succeeding
sub-licensee with whom Cell Power Technologies, Inc. (the "Company" or "we")
entered into acquisition and license agreements, we currently hold royalty
rights on all sales of Cellboost units in North America, Mexico, Puerto Rico,
the US Virgin Islands, the Caribbean and Israel. In addition, we have exclusive
sub-distribution rights of Cellboost in Latin and South America, which is
defined as all countries south of Mexico and north of Tierra Del Fuego,
Argentina.

We were incorporated in the State of Florida in January 2001 under the name
"e-The Movie Network, Inc." to sell movie videos over the Internet. On April 29,
2004, our name was changed to Cell Power Technologies, Inc. Our original
business plan never materialized and, in November 2003, we entered into an
agreement with the holders of the membership interests in Cell Power
Technologies LLC, a Delaware limited liability company, pursuant to which we
issued shares of our common stock for all outstanding membership interests in
Cell Power Technologies LLC. Following the transaction, Cell Power Technologies
LLC became a wholly owned subsidiary of our company.

CELLBOOST PRODUCT

Cellboost is a patented simple disposable power source encased in a hard shell
of plastic with a phone specific plug providing instant talk time to dead phone
batteries as well as serving as a charging device for cellular phones. The
device attaches to the charger port of a cell phone and delivers enough energy
to the phone to enable up to 60 minutes of extra talk time. Cellboost is
intended to supply a needed energy source for built in phone batteries, thereby
avoiding the "dead" cell phone phenomenon. Smaller than a matchbook, Cellboost
comes in phone specific models to fit most cellphones and includes a portable
battery with a non-degenerating three-year shelf life. Cellboost is currently
available in ten different models that are compatible with Nokia, Motorola, Sony
Erickson, Samsung, LG, Sanyo and Siemens cell phones. Each Cellboost has a
plastic cap which makes their storage in pocketbooks or pockets convenient. The
caps are color-coded to be representative of the brand of phone that the
Cellboost works with.

Cellboost was developed by Jumpit AS ("Jumpit"), a private company based in
Oslo, Norway. In December 2001, Jumpit applied for patent protection for the
backup battery for a rechargeable phone. In March 2004, the United States Patent
Office granted the patent. Patent applications are pending in other parts of the
world, including South and Latin America.

OUR RIGHTS TO CELLBOOST PRODUCT

In February 2003, E & S International Enterprises, Inc. ("E & S"), a
California-based electronics distributor, entered into a worldwide exclusive
license agreement, as subsequently amended, with Jumpit for the distribution of
the Cellboost battery. E & S subsequently trademarked the name Cellboost. Under
the license agreement, E & S must meet certain performance targets on an annual
basis in order to maintain exclusive distribution rights in its agreement with
Jumpit. The license continues through February 2013, and contains a provision in
which six months prior to its scheduled expiration date of the license, the
parties can agree to consider, in good faith, the basis for an extension of the
agreement.

                                       11




In February 2003, E & S entered into an agreement with Global Link Technologies,
Inc. ("Global Link"), pursuant to which E & S agreed to pay Global Link a
royalty for all sales in the territories below of the Cellboost units in
consideration of Global Link's termination of an agreement that it then had with
Jumpit. Under such agreement, E & S is required to pay Global Link the following
royalties:

* $.10 on net sales made to retailers in the United States, Mexico, Canada and
Israel;

* $.05 on net sales made to distributors in the United States, Mexico, Canada
and Israel; and

* $.075 on all pre-approved net sales made by E & S in South America, which is
defined as south of Mexico and north of Tierra Del Fuego, Argentina including
the Caribbean but not Puerto Rico or the U.S. Virgin Islands).

E & S also granted Global Link the right to serve as exclusive sub-distributor
in Latin America and as a distributor for the United States, Mexico and Canada.
Sales by E & S in Latin America must be pre-approved by Global Link. Global
Link's license agreement expires in February 2013, subject to any extension in
the original license agreement between E & S and Jumpit.

In October 2003, Cell Power Technologies LLC, our wholly owned subsidiary, prior
to entering into the Share Exchange Agreement with our company, entered into an
asset purchase agreement with Global Link wherein Cell Power LLC purchased
Global Link's royalty rights with respect to sales in North and Central America,
Mexico, the Caribbean and Israel entitling our company to receive royalties on
the net number of units sold by E & S in those territories. The royalty payments
are divided between two categories, sales to retailers and sales to
distributors. Royalty rates per unit payable to our company with respect to
sales by E & S to retailers and distributors are $0.10 and $0.05, respectively.
These rights expire on February 12, 2013, subject to any extension in the
underlying agreement between Jumpit and E & S.

In December 2003, Cell Power Technologies LLC entered into an amended and
restated amendment agreement with Global Link (the "Global Link Agreement") for
exclusive sub-distribution rights in Latin and South America, comprised of
Global Link's rights under the license agreement as they relate to the sale and
distribution of the Cellboost product in Latin and/or South America (which is
defined as those countries and territories south of Mexico and north of Tierra
Del Fuego). Pursuant to this agreement, we are required to remit royalties to
Global Link through 2005, based on units sold, and to E & S, equal to 50% of
gross profit on units sold by us as an exclusive sub-distributor. The royalty
fees due Global Link can be paid, at our sole discretion, either in the form of
cash or unregistered shares of common stock with a market value equal to the
amount of the obligation.

In January 2005, we received a letter from or on behalf of Global Link together
with a document titled First Amendment to the Amended and Restated Asset
Purchase Agreement (the "First Amendment"). The First Amendment, which we
believe was inappropriately obtained by GBLK and, as a result, is not valid,
provides that the royalty fees payable to GBLK are payable in perpetuity. We do
not believe that the First Amendment is enforceable and intends to vigorously
defend against any claim GBLK may initiate regarding the payment of royalties
after 2005. GBLK has also communicated to us that it may have retained certain
rights under the Amended Agreement with respect to Latin and South America and
that through certain of our actions or inactions the Company may be in breach of
such agreement. We believe that GBLK's contentions are without merit. GBLK has
not initiated any formal claims to date with respect to these assertions
however; the Company cannot guarantee that it would be successful in its defense
against any claims GBLK may initiate with respect to these contentions.

                                       12




CRITICAL ACCOUNTING POLICIES

The Company's condensed consolidated financial statements and accompanying notes
have been prepared in accordance with accounting principles generally accepted
in the United States of America. The preparation of these financial statements
requires the Company's management to make estimates, judgments and assumptions
that affect the reported amounts of assets, liabilities, revenues and expenses.
The Company continually evaluates the accounting policies and estimates it uses
to prepare the condensed consolidated financial statements. The Company bases
its estimates on historical experiences and assumptions believed to be
reasonable under current facts and circumstances. Actual amounts and results
could differ from these estimates made by management.

We do not participate in, nor has it created, any off-balance sheet special
purpose entities or other off-balance sheet financing. In addition, we do not
enter into any derivative financial instruments for speculative purposes.

Intangible assets are carried at cost less accumulated amortization.
Amortization is computed on the straight-line method over the ten-year estimated
useful life of the assets.

We review the carrying value of our intangible assets to determine whether
impairment may exist. We consider relevant cash flow and profitability
information, including estimated future operating results, trends and other
available information, in assessing whether the carrying value of the intangible
assets can be recovered. If it is determined that the carrying value of the
intangible assets will not be recovered from the undiscounted future cash flows,
the carrying value of the assets would be considered impaired. An impairment
charge is measured as any deficiency in the amount of estimated fair value of
the intangible assets over carrying value.

FINANCIAL CONDITION

We are considered a development stage company and have a limited operating
history upon which an evaluation of our prospects can be made. As of April 30,
2005, we had an accumulated deficit of $1,645,303. Our prospects must therefore
be evaluated in light of the problems, expenses, delays and complications
associated with a development stage company.

REVENUES. We currently generate revenues from the collection of royalties
payable to us based on the net number of Cellboost units sold by E & S in North
America, Mexico, Puerto Rico, the US Virgin Islands, the Caribbean and Israel.
These royalty payments are divided between two categories, sales to retailers
and sales to distributors. Royalty rates per unit payable to us with respect to
sales by E & S to retailers and distributors are $0.10 and $0.05, respectively.
Revenues from royalties were $29,910 and $56,426 for the six months ended April
30, 2005 and 2004, respectively. Revenues from our distribution of the Cellboost
product for the six months ended April 30, 2005 amounted to $164,445. We did not
generate revenues from the distribution of the product for the 2004 period.

Our plan is to accelerate the development of new markets for Cellboost in Latin
and South America. We expect to incur significant additional expenditures in
implementing our marketing plan and will likely generate operating losses for
the foreseeable future. There can be no assurance that we will be profitable at
any time in the foreseeable future.

                                       13




OPERATING EXPENSES. Our operating expenses for the six months ended April 30,
2005 and 2004 amounted to $543,479 and $456,308 and were principally comprised
of consulting and professional fees. Commencing January 2005, our payments under
the contract with Superior Associates has been reduced by 50% and our Chief
Executive Officer and President is no longer receiving (nor entitled to) a
salary.

Nonetheless, we expect our operating expenses to increase over the course of
fiscal 2005 as we increase our efforts to develop an indirect distribution
framework in the South American market. We expect to incur significant
additional expenditures in implementing our marketing plan and expect to incur
operating losses in the foreseeable future. There can be no assurance that we
can operate the business profitably now or at anytime in the future.

LIQUIDITY AND CAPITAL RESOURCES

To date, we have funded our operations primarily through the sales of our
securities. Pursuant to a private placement commenced in May 2004 and completed
in October 2004, we raised aggregate gross proceeds of approximately $2,210,000
($2,007,000 net of offering costs) from the sale of 92.08 units of our
securities, with each unit comprised of 32,000 shares of common stock and three
year warrants for an additional 32,000 shares of common stock with a per share
exercise price of $1.25. We also raised an additional $50,000 during fiscal 2004
from the sale of other securities.

As of April 30, 2005, our existing cash resources were approximately $18,000, in
addition to which during May 2005 we collected approximately $175,000 from
royalties and distribution of the Cellboost product which were sold during the
six months ended April 30, 2005. We need to raise additional funds as we believe
our existing cash resources will enable us to maintain operations and meet our
obligations as they come due through the fourth quarter of 2005.

Net cash used in operating activities during the six months ended April 30, 2005
was $535,191 and is primarily attributable to consulting, professional and
marketing fees.

Management intends to seek additional needed funds through financings or other
avenues such as loans, the sale and issuance of additional debt and/or equity
securities, or other financing arrangements. We have no commitments for any
additional funding and no assurance can be given that we will be able to raise
additional funds on commercially acceptable terms or at all. Unless we can raise
needed capital or experience a significant increase in royalty income payable to
us by E & S, we may need to curtail expenditures and cancel or delay our efforts
to establish and expand a marketing presence for Cellboost in South and Latin
America. Commencing January 2005, our monthly operating expenses have been
reduced by $29,500 through the reduction of salaries and consulting fees. There
can be no assurance, however, that these reductions are sustainable or that we
can sustain the business for any significant length of time solely through
initiatives to reduce our costs.

Our continuation as a going concern is dependent upon, among other things, our
ability to obtain additional financing when and as needed, and to generate
sufficient cash flow to meet our obligations on a timely basis. No assurance can
be given that we will be able to obtain such financing on acceptable terms. Our
independent registered public accounting firm, in their reports on our financial
statements for the year ended October 31, 2004 expressed substantial doubt about
our ability to continue as a going concern. These circumstances could complicate
our ability to raise additional capital. Our financial statements do not include
any adjustments to the carrying amounts of our assets and liabilities that might
result from the outcome of this uncertainty.

                                       14




In addition, any future capital raise by our company is likely to result in
substantial dilution to existing stockholders.

IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS

In December 2004, the FASB issued Statement of Financial Accounting Standard
("SFAS") No. 123R "Share Based Payment". This statement is a revision of SFAS
Statement No. 123, "Accounting for Stock-Based Compensation" and supersedes APB
Opinion No. 25, "Accounting for Stock Issued to Employees," and its related
implementation guidance. SFAS 123R addresses all forms of share based payment
("SBP") awards including shares issued under employee stock purchase plans,
stock options, restricted stock and stock appreciation rights. Under SFAS 123R,
SBP awards result in a cost that will be measured at fair value on the awards'
grant date, based on the estimated number of awards that are expected to vest
and will be reflected as compensation expense in the financial statements. This
statement is effective for public entities that file as small business issuers -
as of the beginning of the first interim or annual reporting period that begins
after December 15, 2005.

The Company is currently in the process of evaluating the effect that the
adoption of this pronouncement may have on its financial statements.

In December 2004, the FASB issued Statement Accounting Standard ("SFAS") No. 153
"Exchanges of Nonmonetary Assets". This Statement amends Opinion 29 to eliminate
the exception for nonmonetary exchanges of similar productive assets and
replaces it with a general exception for exchanges of nonmonetary assets that do
not have commercial substance. A nonmonetary exchange has commercial substance
if the future cash flows of the entity are expected to change significantly as a
result of the exchange. The provisions of this Statement are effective for
nonmonetary asset exchanges occurring in fiscal periods beginning after June 15,
2005. Earlier application is permitted for nonmonetary asset exchanges occurring
in fiscal periods beginning after December 16, 2004. The provisions of this
Statement should be applied prospectively.

The adoption of this pronouncement did not have material effect on the Company's
financial statements.

EITF Issue 04-8, "The Effect of Contingently Convertible Instruments on Diluted
Earnings per Share." The EITF reached a consensus that contingently convertible
instruments, such as contingently convertible debt, contingently convertible
preferred stock, and other such securities should be included in diluted
earnings per share (if dilutive) regardless of whether the market price trigger
has been met. The consensus is effective for reporting periods ending after
December 15, 2004.

The adoption of this pronouncement did not have material effect on the Company's
financial statements.

ITEM 3. CONTROLS AND PROCEDURES

EVALUATION OF OUR DISCLOSURE CONTROLS AND PROCEDURES

As of the end of the period covered by this report, we carried out an evaluation
of the effectiveness of the design and operation of our disclosure controls and
procedures (as defined in Exchange Act Rule 13-d-15(e) and 15d-15(e)). Based
upon that evaluation and management's assessment of the potential effect of the
material weakness described below, our Chief Executive Officer (and Principal
Accounting Officer) concluded that as of the end of the period covered by this
Quarterly Report on Form 10-QSB our disclosure controls and procedures were
effective to enable us to record, process, summarize and report information
required to be included in our periodic SEC filings within the required time
period.

                                       15




DISCLOSURE CONTROLS AND INTERNAL CONTROLS

Disclosure Controls are procedures that are designed with the objective of
ensuring that information required to be disclosed in our reports filed under
the Securities Exchange Act of 1934 ("Exchange Act"), such as this quarterly
report, is recorded, processed, summarized and reported within the time periods
specified in the SEC's rules and forms. Disclosure Controls are also designed
with the objective of ensuring that such information is accumulated and
communicated, as appropriate to allow timely decisions regarding required
disclosure. Internal Controls are procedures which are designed with the
objective of providing reasonable assurance that (1) our transactions are
properly authorized, recorded and reported; and (2) our financial statements are
presented in conformity with generally accepted accounting principles.

Our company is not an accelerated filer (as defined in the Securities Exchange
Act) and is currently not required to deliver management's report on our
internal control over financial reporting until our fiscal year ended October
31, 2006.

In connection with the audit of our financial statements for the year ended
October 31, 2004, Marcum & Kliegman LLP, our independent registered public
accounting firm ("Marcum") advised us that it had identified a material weakness
in our controls over financial reporting under standards established by the
Public Company Accounting Oversight Board with respect to our royalty reporting.
The material weakness identified by Marcum relates to our ability to record
royalty revenue, the data for which we obtain from an outside party in reports
that are furnished to us on a calendar quarterly basis, which, as of the quarter
ended January 31, 2005, did not coincide with our fiscal quarters. This required
us to estimate revenue for the final month of each fiscal quarter. Specifically,
Marcum identified the material weakness at our October 31, 2004 year end audit
committee meeting that we held in January 2005. For the year ended October 31,
2004, the effect of this timing difference was not material to our financial
statements.

Accordingly, management did not believe it was necessary to disclose the
existence of a material weakness in the 10-KSB for the year ended October 2004
due to the insignificance of the amount of royalties involved. However, during
the quarter ended January 31, 2005, regardless of the insignificance of the
impact of the amount of royalties involved, our sole director and chief
executive officer identified a material weakness in our internal controls over
financial reporting.

We discussed the aforementioned material weakness in detail with our independent
registered public accounting firm, which firm specifically recommended that we
contact the outside party to request a change in the reporting structure that is
currently provided for under our licensing agreement. We immediately accepted
this recommendation and contacted the outside party to request that the royalty
reports be provided to us in intervals that coincide with our fiscal reporting
periods. The outside party has acknowledged our request and has committed to
provide us with such reports in intervals that coincide with our fiscal quarters
beginning in the quarter ended April 30, 2005. We received the requested reports
for the quarter ended April 30, 2005 in June 2005 and are in the process of
implementing changes which we intend to test during our third quarter.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

There were no changes in our internal controls over financial reporting that
occurred during the quarter ended April 30, 2005 that have materially affected,
or are reasonably likely to materially affect, our internal control over
financial reporting.

                                       16




                           PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

None.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

None.

ITEM 5. OTHER INFORMATION.

None.

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.

31. Rule 13a-14(a) / 15d-14(a) Certification

32. Section 1350 Certification

(b) Reports on Form 8-K

None

                                       17




                                   SIGNATURES

In accordance with the requirements of the Exchange Act the registrant caused
this report to be signed by the undersigned thereunto duly authorized.



DATE: August 15, 2005                     CELL POWER TECHNOLOGIES, INC.

                                          /s/ JACOB HERSKOVITS
                                          --------------------------------------
                                          JACOB HERSKOVITS
                                          CHIEF EXECUTIVE OFFICER
                                          (AND PRINCIPAL FINANCIAL AND
                                          ACCOUNTING OFFICER)



                                       18